Latest metastatic melanoma Stories
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that two-year follow up survival data from its Phase 2b clinical trial in metastatic melanoma were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. In addition, an integrated safety analysis from Phase 1 and Phase 2 solid tumor trials of elesclomol plus paclitaxel versus paclitaxel alone was presented. Elesclomol is an investigational drug candidate that triggers programmed cell death...
Synta Pharmaceuticals Corp., (NASDAQ: SNTA) today announced the publication of new findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that describe the novel mechanism of action of elesclomol: driving programmed cell death (apoptosis) in cancer cells through the selective induction of oxidative stress. Elesclomol is currently in a global, pivotal Phase 3 clinical trial (SYMMETRY(SM)) in combination with paclitaxel for the treatment of metastatic...
A patient at The Angeles Clinic and Research Institute is the first to enter a global, pivotal Phase 3 clinical trial for treating advanced melanoma. The experimental drug, Elesclomol, attacks cancer in an entirely new way and has shown promise in treating metastatic melanoma, delaying progression of the disease and possibly prolonging the lives of patients. Elesclomol has a completely new and distinct mechanism of action from other cancer therapies as it induces a potent stress...
Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs. The researchers also showed that these melanoma cells were less invasive following culture on the microenvironments of hESCs."Our observations highlight the potential utility of isolating the factors within the hESC...
